These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 37470325)
1. Homoharringtonine-Based Induction Therapy Reduces the Recurrence Rate of Pediatric Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Wang B; Wen X; Zhang R; Zhu G; Wu Y; Zhang Y; Lin W; Yu J; Fan J; Li J; Yang J; Qin M; Zheng H Cell Transplant; 2023; 32():9636897231183559. PubMed ID: 37470325 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815 [TBL] [Abstract][Full Text] [Related]
3. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206 [TBL] [Abstract][Full Text] [Related]
4. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene]. Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983 [No Abstract] [Full Text] [Related]
5. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931 [TBL] [Abstract][Full Text] [Related]
6. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550 [TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
9. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361 [TBL] [Abstract][Full Text] [Related]
11. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982 [TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution. Lin CH; Chen TC; Shih YH; Chou CW; Hsu CY; Li PH; Teng CJ J Int Med Res; 2022 Feb; 50(2):3000605221078466. PubMed ID: 35187981 [TBL] [Abstract][Full Text] [Related]
13. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis]. Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136 [No Abstract] [Full Text] [Related]
14. Pediatric acute myeloid leukemia patients with Yang W; Qin M; Jia C; Yang J; Chen W; Luo Y; Jing Y; Wang B Hematology; 2022 Dec; 27(1):583-589. PubMed ID: 35617149 [TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and Relapse Prediction Model of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Acute Leukemia]. Wang XN; Zhang Y; Liu XW; Ren J; Zhao J; He PC Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):696-702. PubMed ID: 34105459 [TBL] [Abstract][Full Text] [Related]
17. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia. Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575 [TBL] [Abstract][Full Text] [Related]
18. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582 [TBL] [Abstract][Full Text] [Related]
19. [Clinical Analysis for Patients with AML Treated after Allo-HSCT]. Wang QY; Dong YJ; Liang ZY; Yin Y; Liu W; Xu WL; Sun YH; Han N; Li Y; Ren HY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1105-1114. PubMed ID: 32798384 [TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]